Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
about
EPMA position paper in cancer: current overview and future perspectives.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.Cancer diagnostics and treatment: are we ready to implement PPPM?DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience
P2860
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Dihydropyrimidine dehydrogenas ...... within personalized medicine?
@ast
Dihydropyrimidine dehydrogenas ...... within personalized medicine?
@en
type
label
Dihydropyrimidine dehydrogenas ...... within personalized medicine?
@ast
Dihydropyrimidine dehydrogenas ...... within personalized medicine?
@en
prefLabel
Dihydropyrimidine dehydrogenas ...... within personalized medicine?
@ast
Dihydropyrimidine dehydrogenas ...... within personalized medicine?
@en
P2093
P2860
P50
P1433
P1476
Dihydropyrimidine dehydrogenas ...... within personalized medicine?
@en
P2093
Guido Bocci
Paolo Simi
Ron H van Schaik
P2860
P2888
P304
P356
10.1007/S13167-010-0041-2
P577
2010-07-25T00:00:00Z